about
Molecular epidemiology of hepatitis C virus genotype 4 isolates in Egypt and analysis of the variability of envelope proteins E1 and E2 in patients with chronic hepatitisRibavirin increases mitogen- and antigen-induced expression of CD40L on CD4+ T cells in vivoHCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitorsIn vivo, high-field, 3-Tesla 1H MR spectroscopic assessment of liver fibrosis in HCV-correlated chronic liver disease.Primary yolk sac tumor of the liver: incidental finding in a patient transplanted for hepatocellular carcinoma.Percutaneous laser ablation of hepatocellular carcinoma in patients with liver cirrhosis awaiting liver transplantation.Liver transplantation for the treatment of nodular regenerative hyperplasia.Comparative evaluation of percutaneous laser and radiofrequency ablation in patients with HCC smaller than 4 cm.Downstaging disease in patients with hepatocellular carcinoma outside up-to-seven criteria: Strategies using degradable starch microspheres transcatheter arterial chemo-embolization.Morphological and functional features of hepatic cyst epithelium in autosomal dominant polycystic kidney disease.Epidemiology and outcome of hepatitis C relapse in transplant recipients.Hepatitis C virus recurrence and immunosuppression-free state after liver transplantation.A simple rule to personalize standard dual therapy across all genotypes in naive chronic hepatitis C patients: the TT4 randomized trial.Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen.Liver elasticity in NASH patients evaluated with real-time elastography (RTE).Standard bowel cleansing is highly ineffective in cirrhotic patients undergoing screening colonoscopy.Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort.Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids.HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome.Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression.Obscure gastrointestinal bleeding as first symptom of eosinophilic jejunitis in a liver transplant recipient: diagnosis and treatment with single balloon enteroscopy.Severe drug induced acute hepatitis associated with use of St John's wort (Hypericum perforatum) during treatment with pegylated interferon α.Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late.An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C.Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C.Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin.A Bayesian methodology to improve prediction of early graft loss after liver transplantation derived from the liver match study.Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonrePlasma/erythrocyte ribavirin x100 ratio as an indicator of sustained virological response in HCV genotype 1 patients with early virological response.Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.Vitamin D3 modulates T lymphocyte responses in hepatitis C virus-infected liver transplant recipients.Correlation between liver fibrosis and inflammation in patients transplanted for HCV liver disease.One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis.A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B.Ab initio calcineurin inhibitor-based monotherapy immunosuppression after liver transplantation reduces the risk for Pneumocystis jirovecii pneumonia.
P50
Q27469459-7B6F76D6-8AEB-4805-9AB2-0D6BBD3B8BC3Q27480732-E39E8B3A-F54F-47C9-BB36-E882FCF367D9Q28481038-2E6BC75D-2E30-4003-BF1E-2E68C93BFCCAQ31151404-8F23B27B-9E5E-4600-944E-2FAABDAFA12CQ33325324-68FABB36-828F-4DB3-9292-675747888A0CQ33426681-9F4DAE26-4AA1-498D-85A8-EE6C5459138BQ33907742-3EBFCADC-B24B-4217-A454-1C4CA9F8C8A7Q35052932-8BEED404-7000-4B0E-9761-DE5E95183A55Q35790414-5A6F139E-4BF5-44B5-B8F1-C8E2EAA9FECFQ36559639-7655196E-A978-4BF8-A419-730878D9370CQ37916820-38EE9B9E-5160-4357-A733-BA97C59202A3Q38053172-516FF2EA-76AA-46D8-A371-36BE0262969EQ39010297-4AFF942E-3DAD-42D0-9E92-C00596956957Q39135660-C7EED4B2-F1B8-4178-8D81-AF541F722288Q39651620-86754363-7D2F-4933-8631-3741C4425750Q41145248-6D08391E-3ACD-4683-BAE5-E1C0023DBF74Q41175307-AC43DD71-0997-485F-939A-8E3FDF1796D9Q41341706-1D4CADD4-FDA5-4D2C-844F-54F99B4EAE77Q41412082-22167319-B1C7-45FE-B75F-D0383510A083Q41512202-CB9A5B83-0DBD-45D0-82EF-B7078713DDBBQ41579095-16249451-403A-454A-9E9A-5DF3458D7CC0Q41632541-FF64454A-4554-4F3F-AACD-AA06651B244AQ41651814-74EBD3A7-3FAA-440C-9EF9-D1771FD119BAQ41864587-DA3BD951-D10C-48E2-9395-12A7C3B3AE5EQ41888304-2A9ADFB2-B2D5-40FE-A49D-1E974DBF363EQ42207323-5FD37156-6DE5-437C-9EC6-D9FDDC9C5D4AQ42209453-40EC961B-C82E-4450-9D63-C9DF14597473Q42230987-8435E001-62CA-4F89-9429-24FFBE9AB80BQ42249962-E1B160D4-D8BF-4D35-A3C4-E4951D446ADEQ42637095-A3F45CB4-5222-4086-9C47-489649F3FF0AQ42973710-29CF9635-8A40-423E-B5A9-BFE18A47539CQ42980549-AFD09273-CA6D-42C9-8092-6EFFD95F322AQ42998106-CD9D7EB8-3A03-4E0E-96B5-160E265AD083Q42998194-A31F8EE2-812C-4E3D-996C-3DF7D874DBC1Q43033446-3CF11853-5882-47BF-8A3F-470FE7308079Q43040642-539AD5D3-D1C8-49A0-9468-E98697F5789FQ43046773-4DFB6CAF-EA98-4763-9D5C-7CBBC07610B1Q43056952-BC222DEF-2D19-40C1-B2A1-AEE17E091D72Q43208914-55034DA8-9208-4DED-92F4-D90F5EF75AB8Q43278535-8897BD76-4E1E-4FCE-9AED-7149B5910B26
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Angelico
@ast
Mario Angelico
@en
Mario Angelico
@es
Mario Angelico
@nl
type
label
Mario Angelico
@ast
Mario Angelico
@en
Mario Angelico
@es
Mario Angelico
@nl
prefLabel
Mario Angelico
@ast
Mario Angelico
@en
Mario Angelico
@es
Mario Angelico
@nl
P106
P1153
35379834100
P21
P31
P496
0000-0003-2883-9206